548 related articles for article (PubMed ID: 31745548)
21. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
[TBL] [Abstract][Full Text] [Related]
22. N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.
Liu X; Wang CE; Hong Y; Zhao T; Wang G; Gaertig MA; Sun M; Li S; Li XJ
PLoS Genet; 2016 May; 12(5):e1006083. PubMed ID: 27203582
[TBL] [Abstract][Full Text] [Related]
23. Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice.
Petkau TL; Hill A; Connolly C; Lu G; Wagner P; Kosior N; Blanco J; Leavitt BR
Hum Mol Genet; 2019 May; 28(10):1661-1670. PubMed ID: 30624705
[TBL] [Abstract][Full Text] [Related]
24. Mutant huntingtin inhibits the mitochondrial unfolded protein response by impairing ABCB10 mRNA stability.
Fu Z; Liu F; Liu C; Jin B; Jiang Y; Tang M; Qi X; Guo X
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1428-1435. PubMed ID: 30802639
[TBL] [Abstract][Full Text] [Related]
25. Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.
Creus-Muncunill J; Ehrlich ME
Neurotherapeutics; 2019 Oct; 16(4):957-978. PubMed ID: 31529216
[TBL] [Abstract][Full Text] [Related]
26. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
27. Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease.
Kim C; Yousefian-Jazi A; Choi SH; Chang I; Lee J; Ryu H
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830381
[TBL] [Abstract][Full Text] [Related]
28. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
[TBL] [Abstract][Full Text] [Related]
29. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
30. Widespread and sustained target engagement in Huntington's disease minipigs upon intrastriatal microRNA-based gene therapy.
Vallès A; Evers MM; Stam A; Sogorb-Gonzalez M; Brouwers C; Vendrell-Tornero C; Acar-Broekmans S; Paerels L; Klima J; Bohuslavova B; Pintauro R; Fodale V; Bresciani A; Liscak R; Urgosik D; Starek Z; Crha M; Blits B; Petry H; Ellederova Z; Motlik J; van Deventer S; Konstantinova P
Sci Transl Med; 2021 Apr; 13(588):. PubMed ID: 33827977
[TBL] [Abstract][Full Text] [Related]
31. HAP40 modulates mutant Huntingtin aggregation and toxicity in Huntington's disease mice.
Chen L; Qin Y; Guo T; Zhu W; Lin J; Xing T; Duan X; Zhang Y; Ruan E; Li X; Yin P; Li S; Li XJ; Yang S
Cell Death Dis; 2024 May; 15(5):337. PubMed ID: 38744826
[TBL] [Abstract][Full Text] [Related]
32. AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes.
Keskin S; Brouwers CC; Sogorb-Gonzalez M; Martier R; Depla JA; Vallès A; van Deventer SJ; Konstantinova P; Evers MM
Mol Ther Methods Clin Dev; 2019 Dec; 15():275-284. PubMed ID: 31737741
[TBL] [Abstract][Full Text] [Related]
33. TRIM37 is a primate-specific E3 ligase for Huntingtin and accounts for the striatal degeneration in Huntington's disease.
Qin Y; Chen L; Zhu W; Song J; Lin J; Li Y; Zhang J; Song X; Xing T; Guo T; Duan X; Zhang Y; Ruan E; Wang Q; Li B; Yang W; Yin P; Yan XX; Li S; Li XJ; Yang S
Sci Adv; 2024 May; 10(20):eadl2036. PubMed ID: 38758800
[TBL] [Abstract][Full Text] [Related]
34. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
[TBL] [Abstract][Full Text] [Related]
35. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
36. Efficient and Precise Processing of the Optimized Primary Artificial MicroRNA in a Huntingtin-Lowering Adeno-Associated Viral Gene Therapy
Wang W; Zhou P; Wang X; Chen F; Christensen E; Thompson J; Ren X; Kells A; Stanek L; Carter T; Hou J; Sah DWY
Hum Gene Ther; 2022 Jan; 33(1-2):37-60. PubMed ID: 34806402
[TBL] [Abstract][Full Text] [Related]
37. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
[TBL] [Abstract][Full Text] [Related]
38. Astroglial monoacylglycerol lipase controls mutant huntingtin-induced damage of striatal neurons.
Ruiz-Calvo A; Bajo-Grañeras R; Maroto IB; Zian D; Grabner GF; García-Taboada E; Resel E; Zechner R; Zimmermann R; Ortega-Gutiérrez S; Galve-Roperh I; Bellocchio L; Guzmán M
Neuropharmacology; 2019 May; 150():134-144. PubMed ID: 30914306
[TBL] [Abstract][Full Text] [Related]
39. Accumulation of Endogenous Mutant Huntingtin in Astrocytes Exacerbates Neuropathology of Huntington Disease in Mice.
Jing L; Cheng S; Pan Y; Liu Q; Yang W; Li S; Li XJ
Mol Neurobiol; 2021 Oct; 58(10):5112-5126. PubMed ID: 34250577
[TBL] [Abstract][Full Text] [Related]
40. Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.
Ceccarelli I; Fiengo P; Remelli R; Miragliotta V; Rossini L; Biotti I; Cappelli A; Petricca L; La Rosa S; Caricasole A; Pollio G; Scali C
Neurobiol Dis; 2016 Feb; 86():41-51. PubMed ID: 26626080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
